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Purpose: SLIT-ROBO signaling acts as a cue in neuronal guidance and plays a role in vasculogenesis and angiogenesis.
The aim of this study is to explore the effects of robo1 and slit2 on the formation of fibrovascular membranes (FVMs) in
samples from patients with proliferative diabetic retinopathy. The effects of advanced glycation end products (AGEs) on
robo1 and slit2 expression in human retinal pigment epithelium (RPE) cells and the role of recombinant N-SLIT2 protein
in human RPE cell regulation were investigated.
Methods: Immunohistochemistry was performed to determine the presence and distribution of robo1 and slit2 in FVMs,
and to confirm the effects of SLIT-ROBO signaling on FVM formation. The expression levels of robo1 and slit2 in RPE
cells under basal and differential concentrations of AGEs were measured using real-time reverse transcription-polymerase
chain  reaction  (RT–PCR),  immunoblotting,  or  enzyme-linked  immunosorbent  assay.  LY294002,  an  inhibitor  of
phosphoinositide 3-kinase (PI3K), was used to help determine the AGE signaling mechanism. Recombinant N-SLIT2
protein was used to study the effects of slit2 on RPE cells in vitro. Cell proliferation, migration, and cell cycling were
assessed using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay assay (MTT) assay, a Boyden
chamber assay, and flow cytometry. Real-time RT–PCR and enzyme-linked immunosorbent assay were used to study
vascular endothelial growth factor (VEGF) mRNA expression in and VEGF protein secretion from RPE cells.
Results: Robo1 and Slit2 were expressed in FVMs in RPE cells coimmunostained for pancytokeratin. AGEs resulted in
an increase in robo1 and slit2 levels in RPE cells, and inhibition of PI3K-blocked robo1 and slit2 expression. Recombinant
N-SLIT2 protein increased proliferation, attachment, and migration of the RPE cells, and these cells demonstrated
significant accumulation in the S phase compared to control cells. Furthermore, RPE cells treated with exogenous N-
SLIT2 protein had higher levels of VEGF mRNA expression and VEGF protein secretion (p<0.05).
Conclusions: Robo1 and slit2 may play a role in the formation of FVMs. The presence of AGEs increased levels of robo1
and slit2 in human RPE cells via signaling through the PI3K/Akt pathway. Recombinant N-SLIT2 protein increased the
biologic activity of RPE cells, as well as the expression of VEGF. From these results, we may conclude that SLIT-ROBO
signaling potentially contributes to the development of diabetic retinopathy.
Diabetic  retinopathy  is  a  leading  cause  of  visual
impairment  and  blindness  [1].  Hyperglycemia  plays  an
important role in the pathogenesis of diabetic complications
by increasing the levels of advanced glycation end-products
(AGEs), which are late products of nonenzymatic glycation
[2]. The accumulation of AGEs appears to be a key factor in
the development of diabetic retinopathy. AGEs are thought to
promote many diabetic complications, including retinopathy,
nephropathy, neuropathy, and cardiovascular disease [3,4].
The  retinal  vasculature  is  particularly  vulnerable  to
damage in patients with diabetes; however, other types of cells
in the retina are also at risk. Notable among these cells are
retinal pigment epithelium (RPE) cells, which form part of the
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blood-retinal  barrier  and  perform  functions  crucial  to  the
maintenance  of  the  visual  system  [5].  It  was  previously
demonstrated that persistently high glucose levels may induce
the proliferation of RPE cells. RPE cells play an important
role  in  the  pathogenesis  of  diabetic  proliferative
vitreoretinopathy  by  migrating  through  retinal  breaks  and
contributing to the formation of proliferative membranes. In
previous  studies,  RPE  cells  were  demonstrated  to  secrete
many  different  growth  factors,  and  vascular  endothelial
growth factor (VEGF) was believed to play an important role
in the neovascularization of the retina [6].
The  SLIT-ROBO  signaling  cascade  includes  the  Slit
family  of  secreted  proteins  (Slit1,  2,  and  3)  and  their
corresponding receptors (Robo1, 2, 3, and 4). Although first
characterized in neuronal development [7], Slit2 was recently
found to interact with Robo1 to mediate repulsive cues in
myogenesis [8], leukocyte chemotaxis [9], and endothelial
cell migration. Slit2 has been widely identified in various
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1526human cancers, and the interaction between Slit2 and Robo1
is thought to induce tumor angiogenesis [10]. In addition, Slit2
has been identified as a regulator of adult lymphangiogenesis
[11].
The full-length Slit2 protein is a 200 kDa secreted ligand
that is cleaved into two smaller fragments, a 140 kDa N-
terminal  product  (N-Slit2)  and  a  50–60  kDa  C-terminal
product (C-Slit2). N-Slit2 remains tightly bound to the cell
membrane, whereas C-Slit2 is readily diffusible [12]. Little is
known about the amino acid motifs involved in the interaction
between N-Slit2 and the cell membrane, or whether further
enzymatic  processing  might  be  necessary  to  generate
additional  N-terminal  fragments  in  vivo.  However,  many
studies have found that N-Slit2 binds to Robo, which is a
single-pass transmembrane receptor [13].
In a previous study, we confirmed the presence of Robo1
and 4 expression in RPE cells. We indicated that Robo1 and
4 may play a role in the formation of FVMs in cells [14,15].
Robo1  and  Robo4  may  also  be  involved  in  retinal
vasculogenesis and angiogenesis. In this study, we found that
the FVMs stained positively for Robo1 and slit2 in RPE cells.
We also investigated Robo1 and slit2 expression in cultured
human RPE cells under different concentrations of AGEs or
LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K).
Using recombinant human N-terminal Slit2 protein (N-Slit2),
we were able to study the role of slit2 as a neuronal guidance
cue in RPE cells.
METHODS
Tissue samples: This study protocol was approved by the
Ethics Committee of Peking University, and informed consent
was obtained from all patients according to the World Medical
Association Declaration of Helsinki. FVM specimens were
surgically removed from the eyes of five patients with type 2
diabetes and proliferative diabetic retinopathy (PDR; 5 eyes),
and  who  were  undergoing  pars  plana  vitrectomy  with
membrane peeling. Study patients consisted of three males
and two females, with ages ranging from 50 to 70 years (mean
age  of  61.6±8.29  years).  The  duration  of  diabetes
pathogenesis  ranged  from  6  to  25  years  (mean  duration
16±7.78 years). The five FVM specimens were fixed in a test
tube  containing  4%  paraformaldehyde  (PFA),  and  were
subsequently  embedded  in  optimum  cutting  temperature
compound for immunohistochemistry.
Cell culture and reagents: Human RPE cells (D407 cell line)
were obtained from the American Tissue Culture Collection
(Manassas, VA) and were cultured in Dulbecco’s Modified
Eagle Media (DMEM; Gibco, Invitrogen, Grand Island, NY)
with 10% fetal bovine serum (FBS, Gibco, Invitrogen), 100
units/ml penicillin, and 100 μg/ml streptomycin (Sigma, St.
Louis, MO) at 37 °C under 5% CO2 and 95% humidity. RPE
cells were plated in 6-well culture dishes and were used for
experiments  at  80%–90%  confluence.  The  cells  were
incubated in fresh serum-free medium for 24 h before use in
experiments.  For  culture  under  conditions  for  AGEs
(Biovison, Linda Vista Avenue, CA), cells were treated using
unmodified BSA or AGEs (10, 20, 50, 100 ug/ml). To assess
PI3K/Akt activity, the pharmacological inhibitor LY294002
(Sigma, St. Louis, MO) was added to the culture medium at a
final concentration of 10 μM for 30 min before treatment with
AGE  (20  ug/ml).  To  culture  cells  in  the  presence  of
recombinant N-SLIT2 protein (PeproTech, Rocky Hill, NJ),
cells were treated at final concentrations of 0.1, 1, 10, and 100
ng/ml protein.
RNA isolation: Total RNA was isolated using Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. After being washed with 75% ethanol, the final
RNA  extracts  were  eluted  in  20  μl  distilled  diethyl
pyrocarbonate–treated water. The concentration and purity of
RNA were measured using a spectrophotometer. All RNA
preparations had an OD260:OD280 ratio of 1.9–2.0.
Real-time  PCR:  Retinal  RNA  (2  μg)  was  converted  into
cDNA in a total reaction volume of 25 ul, containing 1 ug
oligo (dT)15, 5 μl Moloney Murine Leukemia Virus (M-
MLV)  5×  reaction  buffer,  1.25  ul  deoxy-ribonucleoside
triphosphate mix (dNTPs), 25 U recombinant RNasin RNase
inhibitor,  and  200  U  M-MLV  reverse  transcriptase.  The
mixture  was  incubated  for  60  min  at  42  °C,  and  reverse
transcription was terminated by incubation of the solution at
95 °C for 5 min [14]. Real-time PCR assays were performed
according  to  the  manufacturer’s  instructions  (Fermentas,
Burlington, Canada). The absorbance were measured at 562
nm on a plate reader. Use the standard curve to determine the
protein  concentration  of  each  sample.  Sequence-specific
primers for β-actin (ACTB), human Robo1, human slit2, or
human  VEGF  (Table  1)  were  used.  Real-time  PCR  was
performed using IQ Supermix (Bio-Rad, Hercules, CA), with
each 20 μl reaction mixture containing 2 μl cDNA, 7.2 μl
sterilized water, 10 μl SYBR Green Real-time PCR Master
Mix (2×), and 0.8 μl of each primer (10 μM). Amplification
was performed in 96-well plates using an iCycler iQ real-time
detection  system  (Bio-Rad).  Thermocycling  conditions
consisted  of  3  min  at  95  °C  to  activate  the  iTaq  DNA
polymerase, 35 cycles of 20 s each, a 95 °C denaturation step,
a 15 s 61 °C (VEGF and SLIT2) or 63 °C (ACTB and Robo1)
annealing step, and a 15 s 72 °C extension step. Robo1, slit2,
and VEGF were normalized to ACTB expression and DNA
levels were calculated using the following equation: Fold
change=2−ΔΔct.
Western blot analysis: Cells were washed three times in ice-
cold phosphate-buffered saline (PBS, 4 °C, 8.00 g NaCl, 0.20
g KCl, 0.24 g KH2PO4, and 1.44 g Na2HPO4 in 1 l distilled
water, pH 7.4) every 5 min at room temperature and prepared
using protein extraction and protease inhibitor kits (Pierce,
Rockford, IL). Cell lysates were cleared by centrifugation at
12,000× g at 4 °C. The supernatant was collected, and the
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1527protein content of each lysate was measured using a BCA
Protein Assay Kit (Tianlai Shengwu Jishu, Tianlai, China)
according to the manufacturer’s instructions. The standard
and  sample  were  added  into  a  microplate  well.  It  was
incubated at 37 °C for 30 min. Equal amounts (20 μg) of
protein were electrophoresed on 10% sodium dodecyl sulfate
(SDS) polyacrylamide gel and analyzed by immunoblotting.
Primary antibodies used include anti-Robo1 (1:500; Abcam,
Cambridge, UK, Cat No. ab7279) and β-actin (1:1000; Boster,
Wuhan, China). Membranes were washed and incubated with
peroxidase-conjugated secondary antibodies (1:6000; Boster,
China),  and  proteins  were  visualized  using  enhanced
chemiluminescence  western  blotting  detection  reagents
(Pierce) according to the manufacturer’s recommendations.
Robo1 band densities were normalized to each β-actin internal
control.  All  immunoblots  were  repeated  three  times,  and
qualitatively similar results were obtained across blots.
Measurement of enzyme-linked immunosorbent assay: Cell
supernatants were analyzed for slit2 (Cusabio Biotech Co.,
Wuhan, China) and VEGF (R&D Systems, Minneapolis, MN)
levels  using  commercially  available  enzyme-linked
immunosorbent assay (ELISA) kits. Conditioned media were
collected after 24 h of incubation in either AGEs or N-SLIT2
protein, and the media was centrifuged and stored at −70 °C
until analysis. Measurements were conducted according to the
manufacturer’s instructions, and all samples were assayed in
triplicate and mean values calculated.
Immunohistochemistry: Membrane tissues were snap-frozen
and 6 μm sections were cut. Thawed tissue sections were air
dried, placed in 4% PFA for 20 min for fixation, washed with
PBS, and blocked with 10% normal goat serum for 1 h at
37 °C. Next, 1:100 anti-Robo1 polyclonal antibody (Cat No.
ab7279;  Abcam,  Cambridge,  UK)  and  1:200  anti-slit2
polyclonal antibody (Cat No. AB 5701; Millipore, Temecula,
CA) with 1:100 anticytokeratin antibody (Santa Cruz, Santa
Cruz, CA) was applied to the tissue sections at 4 °C overnight
and  incubated  for  1  h  at  37  °C  with  1:100  fluorescein
isothiocyanate–  and  tetramethylrhodamine  isothiocyanate–
conjugated  goat  antirabbit  and  goat  antimouse  secondary
antibodies (Santa Cruz), respectively. Following incubation,
slides were washed, and cell nuclei were stained with 4’, 6’-
diamino-2-phenylindole (DAPI). Images were acquired with
a fluorescence microscope equipped with a digital camera. For
each of the immunostaining procedures, negative controls
included omission of the primary antibody and use of an
irrelevant polyclonal or isotype-matched monoclonal primary
antibody. In all cases, negative controls showed only faint,
insignificant staining.
In vitro cell proliferation assay: To assess cell proliferation,
a  3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT; Roche, Molecular Biochemicals, Mannheim,
Germany) assay was used. Briefly, RPE cells were plated at
a density of 2×103 cells per well in 96-well culture plates.
After attachment, the culture medium was changed to DMEM
containing 10% FBS, and the cells were incubated for 24 h.
After reaching 80% confluence, the cells were starved with
DMEM containing 1% FBS for 6 h and then treated with
various concentrations of N-SLIT2 protein. After 24 h, MTT
was added to the culture medium and the cells were incubated
for an additional 4 h. Formazan crystals that formed were then
dissolved by the addition of dimethyl sulfoxide (100 μl/well).
Absorbance at 570 nm was measured using an ELISA plate
reader  (Dynatech  Medica,  Guernsey,  UK)  [14].  Each
experimental condition was performed in quadruplicate wells,
and each plate was repeated three times.
Cell attachment assay: Plates (96 well) coated with 1.25 μg/
ml fibronectin in 100 μl PBS were incubated overnight at 4 °C.
RPE cells (1×104) treated with various concentrations of N-
SLIT2 protein (10, 100 ng/ml) were trypsinized, added to each
well, and permitted to attach for 6 h [14]. The cells were then
washed gently twice with PBS, and 150 μl fresh medium with
MTT was added to each well. Absorbance was measured
using an ELISA plate reader at 570 nm. Three different wells
were used to detect cell attachment, and all experiments were
repeated three times.
Cell migration: The cell migration assay was performed as
described previously [14]. Briefly, 2×104 cells were placed in
the upper chamber in a final volume of 200 μl serum-free
medium. Next, 10% FBS with recombinant N-SLIT2 protein
(10, 100 ng/ml) was placed in the bottom chamber for a final
TABLE 1. GENE SUBTYPE OLIGONUCLEOTIDE PRIMERS.
Gene subtype Oligonucleotide primers (5′-3′) Size (bp)
ACTB F: CTTAGTTGCGTTACACCCTT 144
  R: CCTTCACCGTTCCAGTTT  
human Robo1 F: GGAAGAAGACGAAGCCGACAT 104
  R:TCTCCAGGTCCCCAACACTG  
human Slit2 F:CACCTCGTACAGCCGCACTT 107
R:TGTGGACCGCTGAGGAGCAA  
human VEGF F: AGTTCCACCACCAAACATGC 110
  R: TGAAGGGACACAACGACACA  
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1528volume of 600 μl. All migration assays were conducted for 4
h at 37 °C. At the end of the assay, the cells were fixed in 4%
PFA and stained with DAPI for 15 min. The remaining cells
were removed with a cotton bud, and the membrane was
imaged. The number of cells from five random fields of view
was counted.
Flow cytometry: RPE cells (1×106) were seeded in 6-well
plates and treated with recombinant N-SLIT2 protein (10, 100
ng/ml) for 48 h. Cells were detached using ethylene diamine
tetraacetic acid (EDTA), washed in ice-cold PBS (4 °C), and
treated  with  the  BD  Cycletest™  Plus  DNA  Reagent  Kit
(Becton Dickinson) according to the manufacturer’s protocol.
Samples  were  analyzed  using  a  FACS  Caliber  cytometer
(Becton Dickinson). Three samples were used per experiment,
and each experiment was repeated.
Figure 1. Robo1 and slit2 expression in
fibrovascular  membranes  from  a  66-
year-old patient with a 15-year history
of  diabetes.  A,  B,  E,  F:
Immunofluorescent  staining  shows
Robo1-positive (A), slit2-positive (E),
and cytokeratin-positive (B, F) staining
in  fibrovascular  membranes  (FVMs).
C, D, G, H: Cell nuclei were stained
with  4’,  6’  -diamino-2-phenylindole
(DAPI; C, G), and the colocalization of
Robo1 and pancytokeratin (D), and slit2
and cytokeratin (H) are also shown. Bar
graphs denote 100 μm.
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1529Statistical evaluation: All data were evaluated for normality
of distribution. Statistical differences were evaluated using
ANOVA followed by the Student–Newman–Keuls test for
multiple  comparisons.  p<0.05  was  considered  statistically
significant. All data are presented as mean±standard deviation
(SD).
RESULTS
Immunohistochemical detection of robo1 and slit2 in FVMs:
To investigate the presence and distribution of robo1 and slit2
in FVMs, we stained sections using an antirobo1 antibody
(Figure  1A),  an  antislit2  antibody  (Figure  1E),  and  an
anticytokeratin  antibody  (RPE  cell  marker,  Figure  1B,F).
Detection with the robo1 and slit2 antibodies demonstrated
that these proteins were expressed in FVMs. Additionally, we
determined  that  robo1  and  slit2  were  coexpressed  with
cytokeratin, which is a marker of RPE cells.
Effects of advanced glycation end-products and LY294002 on
expressions  of  robo1  and  slit2  mRNA  in  human  retinal
pigment epithelium cells: We observed that the presence of
AGEs (10, 20, 50, or 100 ug/ml) increased robo1 and slit2
mRNA levels in human RPE cells measured using real-time
RT–PCR (Figure 2). These results are representative of three
experiments with similar outcomes. AGEs at a concentration
of 50 ug/ml induced the strongest robo1 mRNA expression
level, with a 3.29 fold increase in robo1 mRNA expression
compared  to  the  control  group  (p<0.01).  It  was  also
determined that LY294002 (10 uM) blocked the expression
of robo1 under AGEs (20 ug/ml; p<0.01; Figure 2A). We also
demonstrated that mRNA levels of slit2 in human RPE cells
increased  after  exposure  to  AGEs.  However,  the  highest
expression  of  slit2  mRNA  was  seen  with  an  AGE
concentration of 20 ug/ml. There was a 3.83 fold increase in
slit2 mRNA expression compared to control (p<0.01). Slit2
expression secondary to AGEs exposure (20 ug/ml) was also
blocked using LY294002 (10 uM; p<0.01; Figure 2B). In
addition, we found that 100 ng/ml AGEs induced a slight
upregulation of robo1 and slit2 mRNA (p<0.05).
Effects of advanced glycation end-products and LY294002 on
Robo1  protein  expression  in  human  retinal  pigment
epithelium cells: We next evaluated whether Robo1 protein
levels  are  also  regulated  in  AGE-treated  RPE  cells.
Immunoblotting was performed using total cell lysates from
RPE cells cultured with various concentrations of AGEs for
24 h. Robo1 protein expression in response to 20 ug/ml AGEs
demonstrated a 2.03-fold elevation compared to the control
group (p<0.01). The AGEs (20 ug/ml) group was then treated
with LY294002, and robo1 expression was demonstrated to
decrease to that of treatment with single AGEs (20 ug/ml;
p<0.01; Figure 3).
Effects of advanced glycation end-products and LY294002 on
secretion of slit2 protein in human retinal pigment epithelium
cells: Slit2 protein secretion by RPE cells was increased in the
Figure 2. Effects of advanced glycation end-products and LY294002 on Robo1 and slit2 mRNA levels in human retinal pigment epithelium
cells as measured by real-time RT–PCR. A: Robo1 expression in human retinal pigment epithelium (RPE) cells was significantly increased
at the mRNA (mRNA) level after a 24 h treatment of advanced glycation end products (AGEs) as measured by real-time RT–PCR. LY294002
(10 uM) blocks the expression of robo1 under conditions of AGEs (20 ug/ml). B: Slit2 expression in human RPE cells was also increased at
the mRNA level after AGEs. The expression of slit2 in response to AGEs (20 ug/ml) decreased after treating cells with LY294002 (10 uM)
versus treating the cells with AGEs (20 ug/ml) alone. Values provided are the mean±SD of three independent experiments. Asterisks denote
values significantly different between the treated and control groups (p<0.05). Double asterisks denote values significantly different between
the LY294002 (10 uM) group and the AGEs (20 ug/ml) group (p<0.01). The relative expression level of the control group cell was set to 1.
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1530presence of various concentrations of AGEs as measured by
ELISA. Cells treated with a concentration of 20 ug/ml AGEs
induced the highest levels of slit2 protein (p<0.01). When the
concentration of AGEs rose to 50 and 100 ug/ml, slit2 protein
expression  was  decreased  compared  to  20  ug/ml  AGEs
(p<0.05). LY294002 was determined to block the expression
of slit2 protein under conditions of AGE treatment (20 ug/ml;
p<0.01; Figure 4).
Effects of recombinant N-SLIT2 protein on the proliferation
of  human  retinal  pigment  epithelium  cells:  We  initially
performed experiments to evaluate whether recombinant N-
SLIT2 protein had any effect on RPE cell proliferation. Cells
Figure 3. Protein expression of Robo1 in human retinal pigment
epithelium  cells  was  measured  by  immunoblotting  with
normalization to β-actin expression in retinal pigment epithelium
cells. A: A representative photograph of the immunoblot analysis for
Robo1 expression in human retinal pigment epithelium (RPE) cells.
B:  Relative  Robo1  protein  levels  between  the  control  group,
advanced glycation end-products (AGEs) group, and LY294002-
treated group. Values provided are mean±SD of three independent
experiments. Asterisks denote values significantly different between
the  treated  group  and  control  group  (p<0.05).  Double  asterisks
denote values significantly different between the LY294002 (10 uM)
group and AGEs (20 ug/ml) group (p<0.01).The pixel intensity of
the control group was set to 1.
were incubated with N-SLIT2 protein at concentrations of 0.1,
1, 10, or 100 ng/ml for 24 h. Among the various concentrations
of N-SLIT2 protein tested, N-SLIT2 protein at a concentration
of  10  ng/ml  or  100  ng/ml  was  observed  to  significantly
increase RPE cell proliferation compared to the control group.
These data suggest that N-slit2 may significantly induce RPE
cell proliferation until a threshold concentration of 100 ng/ml.
N-SLIT2 protein (100 ng/ml) was determined to increase cell
proliferation  by  77%  after  24  h  compared  to  control  cell
proliferation (p<0.05; Figure 5).
N-SLIT2 protein regulates cell attachment and migration: In
the  cell  attachment  assay,  N-SLIT2  protein  (10  ng/ml)
treatment increased the attachment capacity of RPE cells by
2.15 fold (p<0.01; Figure 6) after 6 h compared to the control
group,  and  100  ng/ml  N-SLIT2  protein  increased  the
attachment  by  2.47  fold  compared  to  the  control  group
(p<0.01; Figure 6). Next, we explored the role of N-SLIT2 in
the migration of RPE cells using a modified Boyden chamber
in which RPE cells migrated through a porous membrane. As
shown in Figure 7, the mean number of migrated cells in the
N-SLIT2  protein–treated  RPE  cells  (10,  100  ng/ml)  was
Figure 4. Effects of increasing concentrations of advanced glycation
end-products and LY294002 on the secretion of slit2 protein in
human retinal pigment epithelium cells. Cells were treated with
increasing  concentrations  of  advanced  glycation  end-products
(AGEs) ranging from 10 to 100 ug/ml and LY294002 for 24 h in
serum-free media. Slit2 protein levels in human retinal pigment
epithelium  (RPE)  cells  were  measured  using  an  enzyme-linked
immunosorbent assay, and it was demonstrated that AGEs resulted
in an increase in slit2 secretion. LY294002 was shown to decrease
the expression of slit2 protein under AGE treatment conditions (20
ug/ml). Values are reported as the mean±SD from three independent
experiments. Asterisks denote values significantly different between
the  treated  group  and  control  group  (p<0.05).  Double  asterisks
denote values significantly different between the LY294002 (10 uM)
group and the AGEs treatment (20 ug/ml) group (p<0.01).
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1531significantly higher than the mean number of migrated control
cells (p<0.01). Pretreatment of RPE cells with 10 ng/ml N-
SLIT2 resulted in a 1.69 fold increase in attachment compared
to  the  control  group,  and  100  ng/ml  N-SLIT2  protein
increased attachment by 2.52 fold (Figure 7).
N-SLIT2 protein regulates cell cycle: As shown in Figure 8,
the recombinant N-SLIT2 protein resulted in a significant
reduction of RPE cells in the G0/G1 phase and promoted an
accumulation of cells in the S phase compared to controls. Of
the cells treated with recombinant N-SLIT2 protein, 61.31%
and 58.7% were in the G1 phase when treated with 10 and 100
ng/ml, respectively, compared to 70.73% of the control group
in the G1 phase (p<0.05; Figure 8). Moreover, in RPE cells
treated  with  recombinant  N-SLIT2  protein,  29.01%  and
36.91% were in the S phase of the cell cycle, respectively,
compared to 18.51% of cells in the control group (p<0.05;
Figure 8). There was no significant difference between the
treated and control groups in the number of cells in the G2/M
phase (Figure 8).
Effects of recombinant N-SLIT2 protein on the expression of
VEGF  in  human  retinal  pigment  epithelial  cells:  We
evaluated whether VEGF levels might be affected in RPE cells
treated with N-SLIT2 protein. VEGF mRNA was measured
using real-time RT–PCR, and the result is shown in Figure 9
as a representative experiment of three with similar outcomes.
We found that the VEGF expression in N-SLIT2-treated cells
was significantly increased compared to control cells, and
VEGF mRNA expression levels increased with increasing
recombinant  N-SLIT2  protein  concentrations  (p<0.05).
Recombinant N-SLIT2 protein at a concentration of 100 ng/
Figure 5. Effects of recombinant N-SLIT2 protein on human retinal
pigment epithelium cell proliferation. Retinal pigment epithelium
(RPE) cell proliferation was measured using an MTT assay at 24 h.
Values reported are mean±SD from three independent experiments.
Asterisks denote values significantly different from those of cells
treated with recombinant N-SLIT2 protein compared to control cells
(p<0.05).
ml increased VEGF mRNA levels to 3.98 fold greater than the
control group (p<0.05). We next evaluated whether VEGF
protein levels were also regulated by recombinant N-SLIT2
protein VEGF protein secretion by RPE cells, as measured by
ELISA. Expression of VEGF was found to increase as N-
SLIT2 protein concentrations rose, and a concentration of 100
ng/ml showed the strongest increase in VEGF mRNA (Figure
10) compared to controls (p<0.05).
DISCUSSION
Slit-Robo signaling was first demonstrated as an extracellular
cue  to  guide  axonal  growth.  However,  signaling  via  this
cascade  was  also  demonstrated  to  regulate  blood  vessel
branching. In our previous studies, we found for the first time
that Robo1 and robo4 mRNA and protein were expressed in
the FVMs of human eyes in patients with PDR. The results of
dual-color  immunofluorescence  analyses  of  FVMs  also
showed positive Robo1 and robo4 immunostaining in the
fibrous-like tissue and neovascular endothelial cells. We also
observed that Robo1 and robo4 are expressed in choroid –
retina endothelial (RF/6A) and RPE cells. These signaling
molecules are thought to be involved in retinal vasculogenesis
and angiogenesis [14-16]. Importantly, PDR is caused in part
by increased retinal vascular permeability, new retinal vessel
development,  and/or  loss  of  retinal  capillaries  [17].  Our
current  study  is  the  first  to  examine  whether  Slit-Robo
signaling,  and  specifically  the  effects  of  recombinant  N-
SLIT2 protein, may play a role in human RPE cells under
diabetic conditions.
Figure 6. Effects of recombinant N-SLIT2 protein on the attachment
of  human  retinal  pigment  epithelium  cells.  Cell  attachment  was
assessed after 6 h of incubation and subsequent MTT assay. Values
are reported as mean±SD of four independent experiments. Asterisks
denote values significantly different from those of cells treated with
recombinant N-SLIT2 protein compared to control cells (p<0.01).
The absorbance of the control cells was set to 1.
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1532The fact that RPE cells contribute to the PDR membrane
has  been  confirmed  by  ultrastructural  investigation  [18].
Furthermore, patients with PDR typically have RPE cells that
are  contained  (5%–20%)  in  combined  traction  with
rhegmatogenous retinal detachment membrane [19]. These
observations all indicate that RPE cells migrate through the
retinal  breaks  to  access  the  PDR  membrane  and  may
contribute  to  PDR  progression  by  secreting  angiogenic
factors. Moreover, the RPE is also known to represent the
earliest pathological change in the diabetic retina [20]. In our
study, we demonstrated for the first time that Robo1 and slit2
are expressed in the FVMs of patients’ eyes with PDR. The
results of dual-color immunofluorescence analyses of FVMs
showed positive Robo1 and slit2 staining in RPE cells. Robo1
and slit2 staining partially colocalized with cytokeratin. It is
our hypothesis that RPE cells may autosecrete slit2, which
then binds the single-pass transmembrane receptor, Robo1,
under conditions of diabetic retinopathy. Following this idea,
SLIT-ROBO  signaling  may  actively  participate  in  the
progression  of  diabetic  retinopathy.  These  observations
suggest  that  Robo1  and  slit2  may  be  important  in  the
formation of FVMs.
Most studies have used human primary cells or RPE cells
as an in vitro study model. One of the drawbacks of using
primary RPE cells is that this model provides a limited number
of  cells  and  may  lack  a  consistent  cellular  background.
However, an engineered cell line may be able to overcome
this problem while still maintaining the morphological and
functional characteristics of primary cells [21]. Therefore, we
used the D407 cell line for the majority of our studies. It is
well known that hyperglycemia is a major risk factor for the
development  and  progression  of  diabetic  retinopathy.  A
central question in the understanding of this disorder has been
the  mechanism  through  which  hyperglycemia  results  in
diabetic  retinopathy.  Although  chronic  hyperglycemia  is
known to affect gene expression in several different tissues
and cells [22], changes in Robo1 and slit2 levels were not
examined in the present study. AGEs are believed to be the
late  products  of  nonenzymatic  glycation  linked  with  the
development  of  diabetic  retinopathy.  In  this  study,  we
incubated RPE cells in varying concentrations of AGEs and
used  real-time  RT–PCR,  immunoblotting,  and  ELISA  to
demonstrate that AGEs promote the upregulation in Robo1
and  slit2  expression.  AGEs  supplemented  at  a  final
concentration of 20 ug/ml or 50 ug/ml induced the strongest
Robo1  and  slit2  expression.  Interestingly,  when  the  AGE
concentration rose to 100 ug/ml, Robo1 and slit2 expression
decreased compared to that seen with 20 ug/ml AGEs. These
results are similar to a previously published study where a
concentration of 20 μg/ml AGEs resulted in increased cell
numbers;  however,  it  was  postulated  that  higher
concentrations of AGEs may cause a reduced rate of cell
division, an increased frequency of apoptosis, or both [23].
This suggests to us that robo1 and slit2 may be involved in the
pathologic action of AGE. PI3K and its downstream target
molecule, serine-threonine kinase (Akt), are important in the
regulation  of  several  different  cellular  responses  [24].
Inhibition of this pathway may be considered as a promising
method  to  block  RPE  cell  response  in  proliferative
retinopathies  [25].  We  studied  the  PI3K/Akt  signaling
Figure  7.  Effects  of  recombinant  N-
SLIT2 protein on human retinal pigment
epithelium  cell  migration.  The
migratory activity of cells was estimated
based on the number of cells that had
traveled  through  the  filter  of  the
chamber.  A:  Control  human  retinal
pigment  epithelium  migration.  B:
Migration  of  cells  treated  with
recombinant N-SLIT2 protein (10 ng/
ml). C: Migration of cells treated with
recombinant N-SLIT2 protein (100 ng/
ml). D: Relative migration of cells in the
control  and  recombinant  N-SLIT2
protein groups. Values are reported as
the mean±SD from three independent
experiments.  The  results  demonstrate
that the number of migratory cells in the
recombinant  N-SLIT2  protein  group
was greater than that in the control group
(D, * p<0.01). Migration of cells in the
control group was set to 1.
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1533pathway using LY294002, a well known inhibitor of PI3K.
We found that LY294002 is able to block the effects of AGEs
(20 ug/ml) on robo1 and slit2 expression in RPE cells (Figure
2, Figure 3, and Figure 4). These findings comprise, to the best
of our knowledge, the first data suggesting a role for the PI3K/
Akt  pathway  in  mediating  AGE  activity  through  the
expression of robo1 and slit2.
It  is  known  that  adult  RPE  cells  are  quiescent  and
differentiated, and they reside in the G0 phase of the cell cycle.
In diseases such as PDR [26], proliferative vitreoretinopathy
[27], and age-related macular degeneration [28], attachment
of cells to the retinal surface, spreading of cells along the
surface, and cellular migration with subsequent membrane
formation [29,30] are the initial pathophysiological events. In
this study, human RPE cells were incubated in recombinant
N-SLIT2 protein (0.1, 1, 10, 100 ng/ml) to evaluate the effects
of N-SLIT2 on RPE cell proliferation. We found that the N-
SLIT2 protein significantly increases RPE cell proliferation
compared to the control group. Additionally, we observed that
recombinant N-SLIT2 protein may play a role in many of the
processes involved in the early events of pathogenesis. For
example, we found that a concentration of 10 and 100 ng/ml
N-SLIT2 protein increases both the attachment and migration
of RPE cells. At the same time, we also found that 10 and 100
ng/ml  recombinant  N-SLIT2  protein  causes  significant
Figure  9.  Effects  of  recombinant  N-SLIT2  protein  on  vascular
endothelial growth factor mRNA levels in human retinal pigment
epithelium cells. Vascular endothelial growth factor (VEGF) mRNA
expression in human retinal pigment epithelium (RPE) cells was
significantly  increased  with  increasing  concentrations  of
recombinant N-SLIT2 protein as measured by real-time RT–PCR 24
h after recombinant N-SLIT2 administration. Values are reported as
the mean±SD from three independent experiments. Asterisks denote
values  significantly  different  between  the  treatment  group  and
control group (p<0.05). The relative expression level of the control
group cell was set to 1.
Figure  8.  Effects  of  recombinant  N-
SLIT2  protein  on  the  cell  cycles  in
human retinal pigment epithelium cells.
A: Cell cycle of control retinal pigment
epithelium (RPE) cells. B: Cell cycle of
RPE cells treated with recombinant N-
SLIT2 protein (10 ng/ml). C: Cell cycle
of RPE cells treated with recombinant
N-SLIT2 protein (100 ng/ml). D: Data
from the RPE cell cycle distribution of
the control group and the recombinant
N-SLIT2  protein  group.  Flow
cytometric  analysis  demonstrates  the
effects of recombinant N-SLIT2 protein
on the human RPE cell cycle. The x-axis
represents  fluorescence  intensity  on  a
logarithmic  scale  and  the  y-axis
represents  the  number  of  events.  The
results show that the fraction of cells in
the  G1  phase  has  decreased  and  the
proportion of cells in the S phase has
increased  in  the  presence  of
recombinant N-SLIT2 protein. Values
are  the  mean±SD  from  three
independent  experiments.  The
proportion of G0/G1, G2, and S phase
cells was demonstrated to be decreased
in RPE cells treated with recombinant
N-SLIT2 protein compared to control
cells (D, *p<0.05).
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1534reductions in the numbers of cells in the G0/G1 phase and an
accumulation of cells in the S phase compared to the control
group.  Taken  together,  these  results  suggest  to  us  that
recombinant N-SLIT2 protein is important in initiating the
pathogenesis of diabetic retinopathy.
VEGF is generally considered to be a key angiogenic
factor in the neovascularization that occurs during PDR [31].
The hyperglycemia that is typically present in human and
experimental diabetic retinopathy has been linked to enhanced
VEGF activity [32,33]. Based on the results shown in Figure
9 and Figure 10, it is clear that the recombinant N-SLIT2
protein promotes a dose-dependent increase in VEGF mRNA
expression as well as VEGF secretion by human RPE cells.
The  goal  of  the  present  study  is  to  examine  whether  the
recombinant N-SLIT2 protein, a neuronal guidance receptor,
may enhance VEGF secretion and thus play a role in VEGF-
induced angiogenesis.
In summary, our study indicates that Slit-Robo signaling
may  play  a  role  in  the  formation  of  FVMs.  Increasing
concentrations of AGEs resulted in increased Robo1 and slit2
expression in RPE cells. The PI3K inhibitor, LY294002, is
able to block the expression of robo1 and slit2 under diabetic
conditions. The recombinant N-SLIT2 protein also results in
the increased proliferation, attachment, and migration of RPE
cells; it also results in an increased number of RPE cells in the
S phase compared to the control group, the recombinant N-
SLIT2 protein treatment of RPE cells increases VEGF mRNA
Figure  10.  Effects  of  recombinant  N-SLIT2  protein  on  vascular
endothelial growth factor protein levels in human retinal pigment
epithelium cells. Vascular endothelial growth factor (VEGF) protein
levels were measured by enzyme-linked immunosorbent assay, and
it was determined that VEGF secretion from human retinal pigment
epithelium (RPE) cells increased in a direct manner with increasing
administration of recombinant N-SLIT2 protein (0.1, 1, 10, 100 ng/
ml). Values are reported as the mean±SD from three independent
experiments. Asterisks denote values significantly different between
the treatment group and control group (p<0.05).
expression and VEGF secretion. Although preliminary, all of
these results suggest to us that Slit-Robo signaling may be
involved  in  diabetic  retinopathy.  Nevertheless,  additional
studies are required to elucidate the precise role of Slit-Robo
signaling in the development of diabetic retinopathy and to
examine its potential role as a therapeutic target.
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